Immuron Ltd
Biopharmaceutical firm developing oral polyclonal antibodies for enteric diseases.
IMRN | US
Overview
Corporate Details
- ISIN(s):
- US45254U1016 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 62 LYGON STREET, 3053 CARLTON, VICTORIA
- Website:
- https://www.immuron.com.au
- Sector:
- Manufacturing
Description
Immuron Ltd. is a clinical and commercial-stage biopharmaceutical company focused on developing and commercializing a novel class of orally delivered, specifically targeted polyclonal antibodies. The company's proprietary technology platform is based on polyclonal immunoglobulins (IgG) derived from hyper-immune bovine colostrum to address unmet medical needs, primarily related to gastrointestinal and enteric diseases. Its commercialized products include Travelan®, for reducing the risk of travelers' diarrhea, Protectyn®, for supporting gut and liver function, and ProIBS®, for relieving symptoms of Irritable Bowel Syndrome. Immuron's clinical pipeline includes therapeutic candidates for infectious diseases such as Clostridioides Difficile and Vancomycin-Resistant Enterococci.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immuron Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immuron Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immuron Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
